China Pharma Holdings, Inc. (CPHI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2546 |
| Open | 0.2492 |
| Bid | 0.2400 x 1800 |
| Ask | 0.2499 x 1100 |
| Day's Range | 0.2300 - 0.2505 |
| 52 Week Range | 0.2000 - 1.1200 |
| Volume | |
| Avg. Volume | 171,027 |
| Market Cap | 11.978M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0790 |
| Earnings Date | May 14, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CPHI
Related Research
- China Pharma Holdings, Inc.Technical Assessment: Bearish in the Intermediate-TermFollowing April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the "500" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%.RatingFair ValueEconomic Moat3 days agoArgus Research
- PR Newswire
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal year ended December 31, 2021.
- PR Newswire
China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended September 30, 2021.
- PR Newswire
China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the financial results for the quarter ended June 30, 2021.
